Alaunos Therapeutics (TCRT) Consolidated Net Income (2016 - 2025)
Historic Consolidated Net Income for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to -$1.2 million.
- Alaunos Therapeutics' Consolidated Net Income fell 321.74% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 million, marking a year-over-year increase of 6607.81%. This contributed to the annual value of -$4.8 million for FY2024, which is 8670.28% up from last year.
- Latest data reveals that Alaunos Therapeutics reported Consolidated Net Income of -$1.2 million as of Q3 2025, which was down 321.74% from -$1.0 million recorded in Q2 2025.
- Alaunos Therapeutics' 5-year Consolidated Net Income high stood at -$755000.0 for Q4 2024, and its period low was -$22.7 million during Q3 2021.
- For the 5-year period, Alaunos Therapeutics' Consolidated Net Income averaged around -$7.8 million, with its median value being -$8.9 million (2023).
- In the last 5 years, Alaunos Therapeutics' Consolidated Net Income tumbled by 2167.58% in 2021 and then surged by 9050.19% in 2024.
- Over the past 5 years, Alaunos Therapeutics' Consolidated Net Income (Quarter) stood at -$11.8 million in 2021, then increased by 20.21% to -$9.4 million in 2022, then increased by 15.62% to -$7.9 million in 2023, then surged by 90.5% to -$755000.0 in 2024, then plummeted by 57.22% to -$1.2 million in 2025.
- Its Consolidated Net Income was -$1.2 million in Q3 2025, compared to -$1.0 million in Q2 2025 and -$1.1 million in Q1 2025.